| Catalog No. | HV986026 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG4-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | PLAB, Placental bone morphogenetic protein, MIC1, NRG-1, PTGFB, NSAID-regulated gene 1 protein, GDF15, NAG-1, MIC-1, Prostate differentiation factor, NSAID-activated gene 1 protein, Growth/differentiation factor 15, Macrophage inhibitory cytokine 1, Placental TGF-beta, GDF-15, PDF |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | Q99988 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -834°C. |
|---|
| Alternate Names | CTL002,CTL-002,CTL002,CAS:2556646-63-8 |
|---|
| Background | Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
